Tuesday, August 19, 2008

Omeros Inks Deal With Norwegian Biotech Firm

Seattle-based Omeros Corporation, a biotech firm which is developing treatments for inflammation and disorders of the central nervous system, said today that it has inked a deal with Norwegian firm Affitech AS. Omeros said that the firms are in an agreement for the discovery and development of fully human antibodies by Affitech AS for Omeros, as part of the Omeros MASP-2 program. According to the firm, the financial terms of the deal includes a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros. A dollar value was not given on the deal. Affitech AS is a developer of human antibody therapeutics.